Description
Trade name:
Cosopt
Compound:
Each 1 ml of solution contains:
Dorzolamide hydrochloride 22.26 mg, which corresponds to a content of dorzolamide 20 mg
Timolol maleate 6.83 mg, which corresponds to a content of timolol 5 mg.
Auxiliary components:
Benzalkonium chloride, sodium citrate dihydrate, mannitol, hydroxyethylcellulose, sodium hydroxide, water for injection.
Properties:
Antiglaucoma drug of combined composition. Contains two active components: dorzolamide hydrochloride and timolol maleate, each of which reduces increased intraocular pressure by reducing the secretion of intraocular fluid. The combined action of these substances in the drug leads to a more pronounced decrease in intraocular pressure.
Dorzolamide hydrochloride is a selective inhibitor of carbonic anhydrase type II. Inhibition of carbonic anhydrase in the ciliary body results in decreased secretion of aqueous humor, presumably by reducing the formation of bicarbonate ions, which in turn slows down the transport of sodium and fluid.
Timolol maleate is a non-selective beta-blocker. Although the exact mechanism of action of timolol maleate in reducing intraocular pressure has not yet been established, several studies have shown a predominant reduction in formation and a slight increase in fluid outflow.
Indications:
Increased intraocular pressure:
-for open-angle glaucoma;
– in pseudoexfoliative glaucoma when monotherapy is insufficiently effective.
Method of administration and dosage:
Cosopt is prescribed 1 drop in the conjunctival sac of the affected eye (or both eyes) 2 times a day.
If Cosopt is prescribed as a replacement for another ophthalmic drug for the treatment of glaucoma, the latter should be discontinued one day before starting Cosopt therapy.
When used in combination with another topical ophthalmic drug, Cosopt should be administered at least 10 minutes apart.
With nasolacrimal occlusion (closing the eyelids) for 2 minutes after instillation of the drug, its systemic absorption decreases, which can lead to an increase in local action.
Contraindications:
– airway hyperreactivity;
– bronchial asthma (including history);
-severe COPD;
– sinus bradycardia;
-SSSU;
– AV block II and III degree without a pacemaker;
– severe heart failure;
– cardiogenic shock; severe renal failure (CC <30 ml/min);
– hyperchloremic acidosis;
-dystrophic processes in the cornea;
-pregnancy;
– lactation period (breastfeeding);
– children and adolescents under 18 years of age (due to insufficient study of efficacy and safety);
– hypersensitivity to the components of the drug.
Precautions:
Like other ophthalmic drugs used topically, Cosopt may be absorbed into the systemic circulation. Since timolol, which is part of the drug, is a beta-blocker, adverse reactions that develop with systemic use of beta-blockers may be observed with topical application of the drug.
If the first signs or symptoms of heart failure appear, the use of Cosopt should be discontinued.
Side effects:
The most frequently observed side effects were visual: burning or itching in the eye, taste distortion, corneal erosions, conjunctival injections, blurred vision, lacrimation.
Storage method:
Store at a temperature not exceeding 15-30 degrees. After opening, store no longer than 28 days.
Package:
The cardboard box contains a plastic dropper bottle of 5 ml and paper instructions.
